Diagnosis and Management of Heart Failure with Preserved Ejection Fraction: 10 Key Lessons

ISSN: 1875-6557 (Online)
ISSN: 1573-403X (Print)

Volume 11, 4 Issues, 2015

Download PDF Flyer

Current Cardiology Reviews

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

Jian'an Wang
School of Medicine Zhejiang University

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Diagnosis and Management of Heart Failure with Preserved Ejection Fraction: 10 Key Lessons

Current Cardiology Reviews, 11(1): 42-52.

Author(s): A. Afsin Oktay and Sanjiv J Shah.

Affiliation: Director, Heart Failure with Preserved Ejection Fraction Program, Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, 676 N. St. Clair St., Suite 600, Chicago, IL 60611, USA.


Heart failure with preserved ejection fraction (HFpEF) is a common clinical syndrome associated with high rates of morbidity and mortality. Due to the lack of evidence-based therapies and increasing prevalence of HFpEF, clinicians are often confronted with these patients and yet have little guidance on how to effectively diagnose and manage them. Here we offer 10 key lessons to assist with the care of patients with HFpEF: (1) Know the difference between diastolic dysfunction, diastolic heart failure, and HFpEF; (2) diagnosing HFpEF is challenging, so be thorough and consider invasive hemodynamic testing to confirm the diagnosis; (3) a normal B-type natriuretic peptide does not exclude the diagnosis of HFpEF; (4) elevated pulmonary artery systolic pressure on echocardiography in the presence of a normal ejection fraction should prompt consideration of HFpEF; (5) use dynamic testing in evaluating the possibility of HFpEF in patients with unexplained dyspnea or exercise tolerance; (6) all patients with HFpEF should be systematically evaluated for the presence of coronary artery disease; (7) use targeted treatment for HFpEF patients based on their phenotypic classification; (8) treat HFpEF patients now by treating their comorbidities; (9) understand the importance of heart rate in HFpEF— lower is not always better; and (10) do not forget to consider rare diseases (“zebras”) as causes for HFpEF when evaluating and treating patients. Taken together, these 10 key lessons can help clinicians care for challenging patients with HFpEF while we eagerly await the results of ongoing HFpEF clinical trials and observational studies.


B-type natriuretic peptide, comorbidities, diagnosis, diastolic heart failure, exercise testing, pulmonary hypertension, treatment.

Download Free Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 11
Issue Number: 1
First Page: 42
Last Page: 52
Page Count: 11
DOI: 10.2174/1573403X09666131117131217

Related Journals

Webmaster Contact: urooj@benthamscience.org Copyright © 2015 Bentham Science